GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cost of Goods Sold

US Stem Cell (US Stem Cell) Cost of Goods Sold : $0.02 Mil (TTM As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cost of Goods Sold?

US Stem Cell's cost of goods sold for the three months ended in Dec. 2022 was $0.01 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2022 was $0.02 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. US Stem Cell's Gross Margin % for the three months ended in Dec. 2022 was 75%.

Cost of Goods Sold is also directly linked to Inventory Turnover. US Stem Cell's Inventory Turnover for the three months ended in Dec. 2022 was 5.00.


US Stem Cell Cost of Goods Sold Historical Data

The historical data trend for US Stem Cell's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cost of Goods Sold Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.11 1.34 0.06 0.05 0.02

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

US Stem Cell Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Stem Cell  (OTCPK:USRM) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

US Stem Cell's Gross Margin % for the three months ended in Dec. 2022 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(0.02 - 0.005) / 0.02
=75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

US Stem Cell's Inventory Turnover for the three months ended in Dec. 2022 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


US Stem Cell Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

USRM to Focus on Animal Health and Lead Pet-Care Innovation

By ACCESSWIRE ACCESSWIRE 10-18-2021

USRM Oral Argument in Appeal from FDA Enforcement Action

By ACCESSWIRE ACCESSWIRE 01-19-2021

U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments

By ACCESSWIRE ACCESSWIRE 09-30-2020

USRM Posts Financial Results for First Quarter 2019

By PRNewswire PRNewswire 05-08-2019

USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

By PRNewswire PRNewswire 11-08-2018

Mark Borman Appointed Chairman of the Board of USRM

By ACCESSWIRE ACCESSWIRE 03-09-2022

Autologous Stem Cell Therapy May Hold Key to Regeneration

By PRNewswire PRNewswire 05-14-2018